Literature DB >> 24189059

Salvage surgery due to bowel obstruction in advanced or relapsed ovarian cancer resulting in short bowel syndrome and long-life total parenteral nutrition: surgical and clinical outcome.

Christina Fotopoulou1, Elena Ioana Braicu, Sara-Lea Kwee, Marc Kuhberg, Rolf Richter, Klaus Pietzner, Aarne Feldheiser, Marcus Bahra, Sven Christian Schmidt, Jalid Sehouli.   

Abstract

OBJECTIVE: Salvage surgery for patients with highly advanced or relapsed epithelial ovarian cancer (EOC) complicated by bowel obstruction and resulting in short bowel syndrome (SBS) constitutes a therapeutic dilemma. Our aim was to evaluate surgical and clinical outcome in these highly palliative situations.
METHODS: We evaluated all patients with EOC who underwent salvage extraperitoneal en bloc intestinal resection with terminal ileostomy or jejunostomy resulting in SBS and total parenteral nutrition owing to bowel obstruction between May 2003 and January 2012 in our institution.
RESULTS: Thirty-seven patients were identified (median age, 58 years; range, 22-71 years), 3 (8.1%) with primary and 34 (91.6%) with relapsed EOC. Five patients (13.5%) were platinum sensitive. Median residual intestinal length was 70 cm (range, 10-180 cm); 21 patients (56.8%) had a residual intestinal length less than 1 m. Operative 30-day mortality and major morbidity rates were 10% and 51%, respectively. Median overall survival was 5.6 months (range, 0.1-49 months). One-year and 2-year overall survival rates were 18.3% (95% confidence interval, 5.1%-31.5%) and 8.1% (95% confidence interval, 0%-18.0)%, respectively. Within a median follow-up period of 5 months (range, 0.2-49 months), 4 patients (10.8%) are still alive. No significant differences in survival were seen between patients with or without major complications, tumor residuals, or residual intestinal length of less than 1 m versus greater than 1 m.
CONCLUSIONS: Salvage palliative surgery in EOC due to bowel obstruction resulting in SBS and in need of long-life total parenteral nutrition is associated with high morbidity rates and low overall survival. These surgeries should ideally be performed only in a multidisciplinary setting with adequate infrastructure and possibility of home care support. Conservative management should be the route of action in the absence of acute abdomen or intestinal perforation.

Entities:  

Mesh:

Year:  2013        PMID: 24189059     DOI: 10.1097/IGC.0b013e31829f81ca

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  5 in total

Review 1.  Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer.

Authors:  Sarah E Cousins; Emma Tempest; David J Feuer
Journal:  Cochrane Database Syst Rev       Date:  2016-01-04

2.  Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer.

Authors:  Rudy S Suidan; Weiguo He; Charlotte C Sun; Hui Zhao; Lois M Ramondetta; Brian D Badgwell; Diane C Bodurka; Karen H Lu; Sharon H Giordano; Larissa A Meyer
Journal:  Int J Gynecol Cancer       Date:  2017-09       Impact factor: 3.437

Review 3.  Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.

Authors:  Shaun Hiu; Andrew Bryant; Ketankumar Gajjar; Patience T Kunonga; Raj Naik
Journal:  Cochrane Database Syst Rev       Date:  2022-08-30

4.  Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer.

Authors:  Robert D Morgan; Sofia Stamatopoulou; Nerissa Mescallado; Geoff Saunders; Richard Welch; Claire Mitchell; Jurjees Hasan; Andrew R Clamp; Gordon C Jayson
Journal:  ESMO Open       Date:  2019-03-21

5.  Surgery due to mechanical bowel obstruction in relapsed ovarian cancer: clinical and surgical results of a bicentric analysis of 87 patients.

Authors:  C Fotopoulou; J Sehouli; R Armbrust; R Chekerov; S Sander; M Biebl; S Chopra; Jonathan Krell; Natasha Rinne; Katherine Nixon
Journal:  Arch Gynecol Obstet       Date:  2021-10-01       Impact factor: 2.493

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.